Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
Alfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, Claude Nicaise, Susan O'Brien, Francis Giles, Moshe Talpaz, Jorge Cortes
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure'. Together they form a unique fingerprint.